MISSISSAUGA, ON, June 11, 2014 /CNW/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced that at its 2014 Annual and Special Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated April 30, 2014 were elected as directors of the Company.
The detailed results of the votes by proxy are as follows:
|
Director Nominees
|
NUMBER OF SHARES
|
PERCENTAGE OF VOTES CAST
|
|
FOR
|
WITHHELD
|
FOR
|
WITHHELD
|
|
Daniel Chicoine
|
3,280,929
|
196,987
|
94.34
|
5.66
|
|
David A. Copeland
|
3,279,013
|
198,903
|
94.28
|
5.72
|
|
Anthony E. Dobranowski
|
3,279,784
|
198,132
|
94.30
|
5.70
|
|
Dr. Henrich R.K. Guntermann
|
3,345,441
|
132,475
|
96.19
|
3.81
|
|
Dr. Klaus von Lindeiner
|
3,280,884
|
197,032
|
94.33
|
5.67
|
|
John C. London
|
3,280,958
|
196,958
|
94.34
|
5.66
|
|
Dr. Jacques Messier
|
3,280,127
|
197,789
|
94.31
|
5.69
|
|
Dr. Theodore H. Stanley
|
3,285,630
|
192,286
|
94.47
|
5.53
|
About Nuvo Research Inc.
Nuvo (TSX:NRI) is a specialty pharmaceutical company with a diverse portfolio of products and technologies. The Company operates two distinct business units: the Topical Products and Technology (TPT) Group and the Immunology Group. The TPT Group has four U.S. Food and Drug Administration (FDA) approved commercial products, a pipeline of topical and transdermal products focusing on pain and dermatology and four drug delivery platforms that support the creation of patented formulations that can deliver actives into or through the skin. The Immunology Group has two commercial products, a development program for the treatment of allergic rhinitis and an immune system modulation platform that has the potential to support treatments for a broad range of immune system related disorders. For additional company information visit www.nuvoresearch.com.
SOURCE Nuvo Research Inc.
Investor Relations, Email: ir@nuvoresearch.comCopyright CNW Group 2014